Remission of chronic anthracycline-induced heart failure: With support from a continuous-flow left ventricular assist device

Texas Heart Institute Journal

Volumn 39, Issue 4, 2012, Pages 554-556

  Khan, Nadeem ^a   Husain, Syed Arman ^a   Husain, Syed Iman ^a   Khalaf, Natalia ^a   George, Joggy ^a   Raissi, Farshad ^a   Segura, Ana Maria ^a   Kar, Biswajit ^a   Bogaev, Roberta C ^a   Frazier, O H ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Anthracyclines adverse effects; Cardiomyopathies chemically induced; Heart failure chemically induced; Heart assist devices; Heart drug effects; Recovery of function; Treatment outcome; Ventricular dysfunction, left

Indexed keywords

ANTHRACYCLINE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; WARFARIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CASE REPORT; CHRONIC DISEASE; DISEASE COURSE; DRUG DOSE TITRATION; DYSPNEA; ECHOCARDIOGRAPHY; EXPLANT; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART PALPITATION; HEMODYNAMIC PARAMETERS; HODGKIN DISEASE; HUMAN; IMPLANTATION; PATIENT MONITORING; REMISSION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOPSY; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; DEVICE REMOVAL; FEMALE; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HODGKIN DISEASE; HUMANS; MICROSCOPY, ELECTRON; PROSTHESIS DESIGN; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84865853447     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Von Hoff DD, Layard M W, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubi-cin-induced congestive heart failure. Ann Intern Med 1979; 91(5):710-7. (Pubitemid 10218041)
2. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115(2): 155-62.
3. Kumar S, Marfatia R, Tannenbaum S, Yang C, Avelar E. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Tex Heart Inst J 2012;39(3):424-7.
4. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55(3):213-20.
5. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49(5):330-52. (Pubitemid 46295436)
6. Ajijola OA, Nandigam KV, Chabner BA, Orencole M, Dec GW, Ruskin JN, Singh JP. Usefulness of cardiac resynchro-nization therapy in the management of doxorubicin-induced cardiomyopathy. Am J Cardiol 2008;101(9):1371-2.
7. Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol 2010;105(4):522-6.
8. Castells E, Roca J, Miralles A, Manito N, Ortiz D, Gonzalez J, et al. Recovery of ventricular function with a left ventricular axial pump in a patient with end-stage toxic cardiomyopathy not a candidate for heart transplantation: first experience in Spain. Transplant Proc 2009;41(6):2237-9.
9. Freilich M, Stub D, Esmore D, Negri J, Salamonsen R, Bergin P, et al. Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant 2009;28(1):101-3.